CBPO News and Press, China Biologic Products Holdings Inc.

Leading English language training provider Meten Holding Group’s (METX) stock has soared 54.5% in price over the past month thanks to the company’s strategic collaboration with AGM Group Holdings. However, given the company’s negative profit margins and mixed financials, ...

Currently trading at less than $1, the shares of China-based BIMI International Medical’s (BIMI) have dipped 72.2% in price over the past year. So, given the company’s weak financials and poor profitability, will its stock be able to regain its momentum? Read more to find out. ...

In its latest 13-F filing, York Capital disclosed total fund portfolio of $695.07M.The fund initiated position in Baidu (BIDU) and 21Vianet (VNET).Closed its position in Willis (WLTW) and China Biologic Products Holdings (CBPO) and Boston Scientific (BSX).Adds position in ...

In its latest 13-F filing, Temasek disclosed 71 total holdings worth $25.5B; actual AUM remains undisclosed.The fund initiated position in China Biologic Products (CBPO) and Roblox (RBLX).Closed its position in Evoqua Water Technologies (AQUA) and Airbnb (ABNB).Trims position in Alibaba ...

Merger activity remained steady last week with six new deals announced. Kansas City Southern receives new superior offer. Three new bank mergers announced last week. For further details see: Merger Arbitrage Mondays - Bank Mergers Dominate

China Biologic Announces Completion of Going Private Transaction PR Newswire BEIJING , April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmac...

China Biologic Products (CBPO) rose 0.3% after a Nasdaq delisting notice indicating today would be its last trading day as it's being taken private.Developing story ... For further details see: China Biologic Products gains on Nasdaq delisting notice for take private

China Biologic Products (CBPO): Q4 Non-GAAP EPS of $0.91 beats by $0.22; GAAP EPS of $0.59.Revenue of $112.2M (+9.8% Y/Y)Press Release For further details see: China Biologic Products EPS beats by $0.22

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020 PR Newswire BEIJING , March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-b...

The Chinese economy’s steady recovery and the impressive GDP growth expected there have whetted investors’ appetite for Chinese stocks. While current regulatory scrutiny of Chinese companies and tensions between Washington and Beijing have resulted in a retreat by stocks includi...